Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Starpharma Holdings Limited ( (AU:SPL) ) has issued an announcement.
Starpharma Holdings Limited reported a significant increase in revenue for the fiscal year ending June 30, 2025, with a 183% rise to $4.9 million, driven by research revenue and increased sales of Viraleze™ and VivaGel® BV. The company also reduced its reported loss by 31% to $10 million, reflecting decreased research and product development expenditures. These financial results indicate a positive trajectory for Starpharma, enhancing its position in the biotechnology industry and potentially benefiting stakeholders through improved financial performance and strategic growth.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which is used to improve health outcomes for patients with significant illnesses like cancer. The company’s portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter products.
Average Trading Volume: 394,942
Technical Sentiment Signal: Hold
Current Market Cap: A$56.46M
For detailed information about SPL stock, go to TipRanks’ Stock Analysis page.